Citigroup Inc Amicus Therapeutics, Inc. Call Options Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$9.55 - $12.09 $906,295 - $1.15 Million	94,900 Added 317.39%	124,800 $1.33 Million
Q2 2024 Aug 12, 2024	SELL	$9.04 - $11.75 $359,791 - $467,650	-39,800 Reduced 57.1%	29,900 $296,000
Q1 2024 May 10, 2024	BUY	$11.43 - $14.24 $124,587 - $155,216	10,900 Added 18.54%	69,700 $821,000
Q4 2023 Feb 09, 2024	SELL	$9.97 - $14.52 $326,019 - $474,804	-32,700 Reduced 35.74%	58,800 $834,000
Q3 2023 Nov 09, 2023	SELL	$11.78 - $13.86 $249,736 - $293,832	-21,200 Reduced 18.81%	91,500 $1.11 Million
Q2 2023 Aug 10, 2023	BUY	$10.72 - $13.3 $428,800 - $532,000	40,000 Added 55.02%	112,700 $1.42 Million
Q1 2023 May 11, 2023	BUY	$10.91 - $13.54 $138,557 - $171,958	12,700 Added 21.17%	72,700 $806,000
Q4 2022 Feb 09, 2023	BUY	$9.89 - $12.7 $197,800 - $254,000	20,000 Added 50.0%	60,000 $732,000
Q2 2022 Aug 10, 2022	BUY	$6.23 - $11.12 $249,200 - $444,799	40,000 New	40,000 $430,000

311

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.72B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.